출혈성 질환 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약물 유형별, 질환 유형별, 유통 채널별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Bleeding Disorders Drugs Market, valued at USD 6.03 Billion in 2024, is projected to experience a CAGR of 6.78% to reach USD 8.94 Billion by 2030. Bleeding disorders drugs are pharmaceutical interventions designed to manage conditions stemming from impaired blood coagulation, such as hemophilia and von Willebrand disease, by facilitating clot formation and mitigating bleeding episodes. The market's expansion is significantly propelled by the increasing global prevalence of these disorders and advancements in diagnostic methodologies that enable earlier detection. Furthermore, continuous innovation in recombinant and non-factor therapies, including the development of gene therapies, enhances treatment efficacy.

Key Market Drivers

The increasing global prevalence of bleeding disorders represents a primary driver for the expansion of the bleeding disorders drugs market. Conditions such as hemophilia and von Willebrand disease affect a substantial patient population, creating an ongoing demand for effective therapeutic interventions. Enhanced diagnostic capabilities, alongside greater public and medical professional awareness, contribute to a higher rate of diagnosis, subsequently increasing the number of identified patients requiring treatment. This expanding patient base directly translates into a heightened need for existing and novel pharmaceutical products designed to manage these complex conditions.

Key Market Challenges

The elevated cost of advanced therapies, particularly gene therapies and extended half-life products, significantly impedes the expansion of the global bleeding disorders drugs market. These high costs directly restrict patient access, especially in low-income regions where the economic burden of treatment is substantial. This limitation is compounded by less developed healthcare infrastructure and inadequate reimbursement policies prevalent in these areas, making it challenging for healthcare systems to procure and provide these expensive yet effective treatments.

Key Market Trends

The shifting treatment paradigm towards gene therapies represents a significant transformation in the global bleeding disorders drugs market. These advanced therapies aim to offer potentially curative or long-lasting solutions, moving beyond the traditional need for frequent factor infusions. This shift dramatically alters disease management by providing sustained endogenous factor production, thereby enhancing patient quality of life and reducing the long-term treatment burden. According to the World Federation of Hemophilia's 2024 Annual Report, the organization formally began tracking these novel treatments by enrolling its first patient in the Gene Therapy Registry in 2024, signaling a concentrated effort by industrial associations to monitor their real-world impact

Key Market Players

• Bayer AG
• Grifols S.A.
• Pfizer Inc.
• Octapharma AG
• Ferring International Center S.A.
• Sanofi S.A.
• Baxter International Inc.
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S

Report Scope:

In this report, the Global Bleeding Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bleeding Disorders Drugs Market, By Drug Type:

• Plasma-derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others

Bleeding Disorders Drugs Market, By Disease Type:

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

Bleeding Disorders Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online

Bleeding Disorders Drugs Market, By End User:

• Hospitals
• Hemophilia Treatment Centers
• Research Institutes
• Others

Bleeding Disorders Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Bleeding Disorders Drugs Market.

Available Customizations:

Global Bleeding Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bleeding Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
  • 5.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
  • 5.2.4. By End User (Hospitals, Hemophilia Treatment Centers, Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Bleeding Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bleeding Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Bleeding Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Bleeding Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By End User

7. Europe Bleeding Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bleeding Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By End User
  • 7.3.2. France Bleeding Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Bleeding Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Bleeding Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Bleeding Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By End User

8. Asia Pacific Bleeding Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bleeding Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By End User
  • 8.3.2. India Bleeding Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Bleeding Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Bleeding Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Bleeding Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By End User

9. Middle East & Africa Bleeding Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bleeding Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Bleeding Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Bleeding Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By End User

10. South America Bleeding Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bleeding Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Bleeding Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Bleeding Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bleeding Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Grifols S.A.
• 15.3. Pfizer Inc.
• 15.4. Octapharma AG
• 15.5. Ferring International Center S.A.
• 15.6. Sanofi S.A.
• 15.7. Baxter International Inc.
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer